Expertise in
6
conditions

Dr. Princy Kumar

Infectious Disease
3800 Reservoir Road NW PHC 5TH Floor
3800 Reservoir Rd NW, 
Washington, DC 
Offers Telehealth
Expertise in
6
conditions
3800 Reservoir Road NW PHC 5TH Floor
3800 Reservoir Rd NW, 
Washington, DC 

Overview

Princy Kumar is an Infectious Disease provider in Washington, Washington, D.c.. Dr. Kumar is highly rated in 6 conditions, according to our data. Her top areas of expertise are HIV/AIDS, COVID-19, Multisystem Inflammatory Syndrome in Children (MIS-C), Thrombectomy, and Endoscopy.

Her clinical research consists of co-authoring 111 peer reviewed articles and participating in 6 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties

Infectious Disease

Licenses

Internal Medicine in DC

Hospital Affiliations

Medstar Georgetown University Hospital

Languages Spoken

English

Gender

Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
CareFirst
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Highmark
  • EPO
  • HMO
  • PPO
Independent Health
  • EPO
  • POS
  • PPO
Johns Hopkins Healthcare
  • HMO
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE-MEDICAID PLAN
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 8 Less Insurance Carriers -

Locations

3800 Reservoir Road NW PHC 5TH Floor
3800 Reservoir Rd NW, Washington, DC 20007

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

6 Clinical Trials

A Prospective and Retrospective Observational Study of Multidrug-Resistant Patient Outcomes With and Without Ibalizumab in a Real-World Setting: United States
A Prospective and Retrospective Observational Study of Multidrug-Resistant Patient Outcomes With and Without Ibalizumab in a Real-World Setting: United States
Enrollment Status: Active_not_recruiting
Publish Date: January 02, 2026
Intervention Type: Other, Biological
A Phase IIb, Multicenter, Open-label, Rollover Study Evaluating the Efficacy, Safety and Tolerability of Long-acting Cabotegravir Plus Long-acting Rilpivirine Administered Every Two Months in HIV-1 Infected Adults Who Are Virologically Suppressed and Participated in Study LAI116482
A Phase IIb, Multicenter, Open-label, Rollover Study Evaluating the Efficacy, Safety and Tolerability of Long-acting Cabotegravir Plus Long-acting Rilpivirine Administered Every Two Months in HIV-1 Infected Adults Who Are Virologically Suppressed and Participated in Study LAI116482
Enrollment Status: Completed
Publish Date: June 11, 2024
Intervention Type: Drug
Study Drugs: Long-acting cabotegravir, Long-acting rilpivirine, Rilpivirine, Dolutegravir
Study Phase: Phase 2
A Randomized, Double-blind, Placebo-Controlled, Phase 2/3 Study to Evaluate the Efficacy and Safety of LY3819253 and LY3832479 in Participants With Mild to Moderate COVID-19 Illness
A Randomized, Double-blind, Placebo-Controlled, Phase 2/3 Study to Evaluate the Efficacy and Safety of LY3819253 and LY3832479 in Participants With Mild to Moderate COVID-19 Illness
Enrollment Status: Completed
Publish Date: April 11, 2024
Intervention Type: Drug
Study Drugs: Bamlanivimab, Etesevimab
Study Phase: Phase 2/Phase 3
A Phase 2/3, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study to Evaluate the Safety and Efficacy of TJ003234 in Subjects With Severe Coronavirus Disease 2019 (COVID-19)
A Phase 2/3, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study to Evaluate the Safety and Efficacy of TJ003234 in Subjects With Severe Coronavirus Disease 2019 (COVID-19)
Enrollment Status: Completed
Publish Date: May 06, 2023
Intervention Type: Drug
Study Drug: TJ003234
Study Phase: Phase 2/Phase 3
A Randomized, Double-blind, Placebo-Controlled, Phase 2 Study to Evaluate the Efficacy and Safety of Mono and Combination Therapy With Monoclonal Antibodies in Participants With Mild to Moderate COVID-19 Illness (BLAZE-4)
A Randomized, Double-blind, Placebo-Controlled, Phase 2 Study to Evaluate the Efficacy and Safety of Mono and Combination Therapy With Monoclonal Antibodies in Participants With Mild to Moderate COVID-19 Illness (BLAZE-4)
Enrollment Status: Completed
Publish Date: July 01, 2022
Intervention Type: Drug
Study Drugs: Bamlanivimab, Etesevimab, LY3853113 Anti-COVID-19 Antibody, VIR-7831 Anti-COVID-19 Antibody
Study Phase: Phase 2
A Phase 3, Multicenter, Expanded Access Study of Ibalizumab Plus an Optimized Background Regimen (OBR) in Treatment-Experienced Patients Infected With Multi-Drug Resistant (MDR) HIV-1
A Phase 3, Multicenter, Expanded Access Study of Ibalizumab Plus an Optimized Background Regimen (OBR) in Treatment-Experienced Patients Infected With Multi-Drug Resistant (MDR) HIV-1
Enrollment Status: Completed
Publish Date: March 11, 2021
Intervention Type: Drug
Study Phase: Phase 3
View 5 Less Clinical Trials

111 Total Publications

Comorbidity and comedication burden in people living with HIV in the United States: updated findings from a contemporary cohort (2020-2024).
Comorbidity and comedication burden in people living with HIV in the United States: updated findings from a contemporary cohort (2020-2024).
Journal: Current medical research and opinion
Published: January 08, 2026
Similar Doctors
Naomi Aronson
Expertise in
1
conditions
Dr. Naomi Aronson
Infectious Disease
Expertise in
1
conditions
Dr. Naomi Aronson
Infectious Disease

Office

6900 Georgia Ave, 
Washington, DC 
 (5.0 miles away)
202-782-1663
Languages Spoken:
English

Naomi Aronson is an Infectious Disease provider in Washington, Washington, D.c.. Dr. Aronson is highly rated in 1 condition, according to our data. Her top area of expertise is Leishmaniasis.

Expertise in
7
conditions
Dr. Amy Klion
Infectious Disease
Expertise in
7
conditions
Dr. Amy Klion
Infectious Disease

Office

9000 Rockville Pike, 
Bethesda, MD 
 (6.4 miles away)
301-435-8903
Languages Spoken:
English

Amy Klion is an Infectious Disease provider in Bethesda, Maryland. Dr. Klion is highly rated in 7 conditions, according to our data. Her top areas of expertise are Loiasis, Spirurida Infections, Secernentea Infections, Helminthiasis, and Tissue Biopsy.

Expertise in
2
conditions
Dr. Christian Ockenhouse
Infectious Disease
Expertise in
2
conditions
Dr. Christian Ockenhouse
Infectious Disease

Office

6900 Georgia Ave, 
Washington, DC 
 (5.0 miles away)
301-319-9473
Languages Spoken:
English

Christian Ockenhouse is an Infectious Disease provider in Washington, Washington, D.c.. Dr. Ockenhouse is highly rated in 2 conditions, according to our data. His top areas of expertise are Malaria and Sepsis.

Frequently Asked Questions about Dr. Princy Kumar

How do I make an appointment with Dr. Princy Kumar?

You can book an appointment with Dr. Princy Kumar by calling their office at 202-342-2400. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Princy Kumar a top-rated expert for HIV/AIDS?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Princy Kumar is classified as an Elite expert for HIV/AIDS, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Princy Kumar specialize in?

While Dr. Princy Kumar is a Infectious Disease, they have specific expertise in HIV/AIDS, COVID-19, and Multisystem Inflammatory Syndrome in Children (MIS-C). MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Infectious Disease.

Does Dr. Princy Kumar participate in research or clinical trials?

Yes. Dr. Princy Kumar has published 111 articles and abstracts on conditions like HIV/AIDS. You can view a list of Dr. Princy Kumar's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Princy Kumar accept my insurance?

Dr. Princy Kumar accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 202-342-2400 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Kumar's expertise for a condition
ConditionClose
View All 12 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile